cariprazine (Reagila®)

Status: Recommended with restrictions

Cariprazine (Reagila®) is recommended as an option for restricted use within NHS Wales.

Cariprazine (Reagila®) should be restricted for use in the following subpopulation within its licensed indication for the treatment of schizophrenia in adults:

for use as a second-line therapy in people with schizophrenia where predominantly negative symptoms have been identified.

Cariprazine (Reagila®) is not recommended for use within NHS Wales outside of this subpopulation.

Final Recommendation: cariprazine (Reagila) 5032 (PDF, 1.5Mb)

Appraisal Report: cariprazine (Reagila) 5032 (PDF, 309Kb)

Medicine details

Medicine name

cariprazine (Reagila®)

Formulation

1.5 mg, 3 mg, 4.5 mg, 6 mg hard capsules

Reference number

5032

Indication

Treatment of schizophrenia in adult patients

Company

Recordati Pharmaceuticals Ltd

BNF chapter

Central nervous system

Assessment type

Resubmission

Status

Recommended with restrictions

Advice number

0822

NMG meeting date

02/03/2022

AWMSG meeting date

27/04/2022

Date of issue

12/05/2022